Abstract:
Summary. Although modern guidelines prefer intravenous over peroral iron formulations in the treatment of dialysis patients, this attitude can be changed after the emergence of newer peroral iron medications, that can provide lower adverse effects rate and higher bioavailability. Incapsulated iron formulations (ex. Fersinol z®) eventually can do the thing and their other components contributes to the antianemic effect realization. Such medication administration is prefferable in iron deficit compensation in patients with malabsorbtion, under multiple simulteneous therapies and with high risk of adverse effects development.
Description:
Centrul Dializă şi Transplant Renal IMSP Spitalul Clinic Republican, Catedra Urologie şi Nefrologie Chirurgicală USMF “N.Testemiţanu”, Centrul Republican de Diagnosticare Medicală, Al V-lea Congres de Urologie, Dializă şi Transplant Renal din Republica Moldova cu participare internaţională (1-13 iunie 2011)
